MACK - Merrimack Pharmaceuticals GAAP EPS of $0.02

2023-05-04 17:47:44 ET

• Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): Q1 GAAP EPS of $0.02.

• Merrimack reported a gain on the sale of assets for the first quarter ended March 31, 2023, of $139 thousand, attributable to an asset purchase option agreement on a preclinical program, compared to $445 thousand related to an asset sale in the same period in 2022.

• Interest income in the first quarter ended March 31, 2023, was $176 thousand compared to no interest income for the same period in 2022.

• General and administrative expenses for the first quarter ended March 31, 2023, were $586 thousand, compared to $577 thousand for the same period in 2022.

• As of March 31, 2023, Merrimack had cash and cash equivalents of $19.4 million, compared to $19.4 million as of December 31, 2022.

• As of March 31, 2023, Merrimack had 14.3 million shares of common stock outstanding.

For further details see: